Auditory Dysfunction and Migraine Link

For many, migraine is synonymous with severe headache. A 2026 review published in the Journal of Neurology argues this view is incomplete. Led by researchers Wandi Xu, Ni Zhai, and Jingyu Chen, the analysis positions migraine as a systemic disorder of multisensory sensitization. Within this framework, auditory dysfunction is not a mere side effect but a core phenotype. The data shows 15% to 49% of migraine patients report symptoms like tinnitus, hyperacusis, or sensorineural hearing loss.

Migraine’s Three-Pronged Attack on the Auditory System

The review synthesizes evidence that migraine pathology disrupts hearing through a “peripheral-to-central continuum” across three interacting axes. The first involves anatomy and fluid dynamics. Specific vulnerabilities in the blood supply and fluid compartments of the inner ear can lead to localized microvascular ischemia and disrupted brain-ear fluid exchange. This creates a fragile environment for the delicate sensory cells of the cochlea.

A second, neurochemical axis operates locally within the inner ear. Imbalances in neurotransmitters like glutamate can lead to excitotoxicity, where nerve cells are overstimulated to the point of damage. Signaling by neuropeptides involved in migraine pain, such as CGRP, and activation of the innate immune system further disrupt the inner ear’s delicate homeostasis. This local chaos is amplified by the third axis: central sensitization in the brain. Here, the brain’s pain and sensory processing networks become hyper-excitable. This state facilitates maladaptive neural plasticity, characterized by impaired efferent gating (the brain’s ability to filter sound) and thalamocortical dysrhythmia, where brain rhythms fall out of sync. This central hyperactivity is a likely driver for the sound intolerance seen in conditions like hyperacusis and misophonia.

Objective Evidence of a Silent Auditory Problem

Patient reports of auditory symptoms are substantiated by hard electrophysiological data. The researchers note that nearly two-thirds of migraine patients exhibit abnormalities on objective tests, even in the absence of overt hearing complaints. These tests can measure the health of the auditory nerve and brainstem pathways or the function of the outer hair cells in the cochlea. This high rate of subclinical dysfunction suggests auditory involvement in migraine is almost the rule, not the exception. It reinforces the concept of migraine as a whole-brain disorder that inevitably touches the auditory pathways, a process detailed in our overview of hearing health from cochlea to cortex.

A New Framework for Treatment Strategies

The traditional, fragmented approach to treating migraine-associated auditory problems has been limited. By clarifying the three-pathway model, Xu and colleagues propose a more targeted framework for therapy, organized by clinical objective.

The first strategy focuses on blocking upstream migraine pathways. This includes established preventive medications that modulate CGRP or serotonin, with the goal of reducing the frequency of migraine attacks that may be driving auditory sensitization. The second aims to protect the cochlear microenvironment. Here, the potential lies in future therapies that could mitigate local excitotoxicity, inflammation, or vascular instability in the inner ear. The third strategy directly addresses central hypersensitivity. This is where neuromodulation techniques, sound therapy, and behavioral interventions come into play. For instance, the principles of cognitive reappraisal for misophonia align with this goal of retraining the brain’s emotional and attentional response to sound. Similarly, understanding central factors is key, as research on CBT-I outcomes shows that baseline neurological states significantly influence long-term treatment success for sleep, a principle that likely applies to auditory disorders.

Implications for Patients and Clinicians

This research has direct practical implications. For patients with migraine, any new or worsening auditory symptom—ringing, fullness, sound sensitivity, or hearing fluctuation—should be discussed with a doctor. It may be a integral part of their migraine disorder, not a separate issue. For clinicians, particularly neurologists and otolaryngologists, it argues for routine auditory screening in migraine patients and a collaborative, cross-disciplinary management approach.

The review calls for more translational research to validate these mechanistic links. Future work needs to establish standardized audiological protocols for this patient group and run clinical trials on the proposed treatment strategies. The ultimate goal is early identification and precise phenotyping, moving from a model of vague comorbidity to one of understood pathophysiology. As the evidence consolidates, it strengthens the argument for viewing and treating migraine through a wider sensory lens, where the health of the ears and the brain are fundamentally connected.